quinazolines has been researched along with cep-32496 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, S; Apuy, JL; Armstrong, RC; Ator, MA; Bhagwat, S; Campbell, BT; Chao, Q; Cramer, MD; Dorsey, BD; Ezawa, M; Faraoni, R; Gardner, MF; Ghose, AK; Gibney, M; Gitnick, D; Gunawardane, RN; Herbertz, T; Holladay, MW; Hua, H; Insko, DE; James, J; Jones-Bolin, S; Lai, AG; Nepomuceno, RR; Rowbottom, MW; Ruggeri, B; Setti, E; Sprankle, KG; Struss, B; Tran, L; Valenta, I; Williams, M | 1 |
| Apuy, JL; Armstrong, RC; Ator, MA; Bhagwat, SS; Cheng, M; Cramer, MD; Dobrzanski, P; Dorsey, BD; Faraoni, R; Gardner, MF; Gitnick, D; Gunawardane, RN; Holladay, MW; Hunter, K; Insko, DE; James, J; Jones-Bolin, S; Nepomuceno, RR; Rowbottom, MW; Ruggeri, B; Williams, M; Yazdanian, M; Zhao, H | 1 |
| Fujinaga, M; Hatori, A; Kawamura, K; Kumata, K; Ogawa, M; Shimoda, Y; Xie, L; Yamasaki, T; Yui, J; Zhang, MR | 1 |
| Agarwal, S; Aheman, A; Chen, Z; De Las Casas, A; Foster, JH; Hu, Y; Jin, J; Li, H; Lu, J; Shi, Z; Su, J; Vasudevan, SA; Woodfield, SE; Wu, D; Xu, X; Yan, Y; Yang, J; Yu, X; Yu, Y; Zhai, Y; Zhang, H; Zhao, Y | 1 |
4 other study(ies) available for quinazolines and cep-32496
| Article | Year |
|---|---|
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (B
Topics: Administration, Oral; Animals; Binding, Competitive; Cell Line, Tumor; Cell Proliferation; Dogs; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles; Macaca fascicularis; Male; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Mutation; Neoplasm Transplantation; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Quinazolines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2012 |
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dogs; Drug Screening Assays, Antitumor; Humans; Macaca fascicularis; Male; Mice; Mice, Nude; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Quinazolines; Rats; Rats, Sprague-Dawley | 2012 |
[(11)C-carbonyl]CEP-32496: radiosynthesis, biodistribution and PET study of brain uptake in P-gp/BCRP knockout mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Carbon Isotopes; Mice; Mice, Knockout; Molecular Structure; Phenylurea Compounds; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Tissue Distribution | 2014 |
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice, Nude; Mice, Transgenic; N-Myc Proto-Oncogene Protein; Neuroblastoma; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |